⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 30, 2017BloodOpen Access

LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis

Sara El Ashkar Juerg Schwaller Tim Pieters Steven Goossens Jonas Demeulemeester Frauke Christ Siska Van Belle Sabine Juge Nancy Boeckx Alan Engelman Pieter Van Vlierberghe Zeger Debyser Jan De Rijck

View Full Paper

Ask AI

Bookmark

Share

Abstract

l LEDGF/p75, an important cofactor required for MLLrearranged leukemia, is not essential for steady-state hematopoiesis.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ashkar et al. (2017) studied this question.

synapsesocial.com/papers/6a0cedfebe0a9f67ad7c765e https://doi.org/10.1182/blood-2017-05-786962

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Multi-omics reveals evolution from CD7-negative T cell dysregulation to EBV-positive LPD after CD7 CAR-T therapyBlood · 2026
2Low Incidence of Cryptic Genetic Marrow Failure in Pediatric Severe Aplastic Anemia Following Negative Clinical WorkupBlood · 2026
3Splicing Factor Mutations in Myeloid MalignanciesBlood · 2026
4Initial fixed low-versus moderate-dose hydroxyurea assignment in the long-term follow-up of the SPRINT cohortBlood · 2026
5Molecular Underpinnings and Prevalence of Donor Cell-Derived Hematologic Neoplasms among Spanish Transplantation CentersBlood · 2026

Immunologic and Plasma-Dependent Mechanisms of Chronic Hemolysis and Hyperhemolysis in Sickle Cell DiseaseBlood · 2026
CD8 T-cell exhaustion linked with CAR T-cell failure can be mitigated by a non-alpha IL2 receptor agonistBlood · 2026
Thrombin-mediated AutoRegulation of FVIII-mimetic antibodies enabling dynamic control of the hemostatic responseBlood · 2026
Peginterferon alfa-2a, bictegravir-emtricitabine-tenofovir alafenamide, and venetoclax in adult T-cell leukemia/lymphomaBlood · 2026
A randomized phase 2 study combining midostaurin, low-dose cytarabine and venetoclax in newly diagnosed AML ≥60 yearsBlood · 2026

More from Blood

More from Harvard University

More from Dana-Farber Cancer Institute

More from KU Leuven

More from University of Basel

More from Ghent University Hospital

More from University Children’s Hospital Basel

More from Cancer Research Institute Ghent